Navigation Links
Sitagliptin, Under Investigation For Type 2 Diabetes

The number of people suffering from diabetes is already over 194 million worldwide and the number is expected to increase by 333 million by 2025. Type II diabetes is also known as non-insulin dependent diabetes // and is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to an elevated glucose. In contrast to Type I diabetes, there is always some endogenous insulin production, and many patients have normal or even elevated blood insulin levels. The disease usually occurs over the age of 40 and treatment involves diet, oral hypoglycemic drugs and exogenous insulin.

However, side effect profile of the given medication, route of administration or difficulties in sustaining glucose control pose serious concerns and necessitate more tolerable treatments that do not cause weight gain and produce less risk of hypoglycemia for patients with type 2 diabetes.

Clinical phase II studies involving Sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

Sitagliptin is expected to lower blood glucose levels by increasing the level of active incretin hormones which increase insulin from pancreatic beta-cells and decrease glucagon from pancreatic alpha cells in a glucose-dependent manner (when blood glucose is elevated and not when blood glucose is low). If approved, Sitagliptin would be a member of a new class of antihyperglycaemic agents called DPP-IV inhibitors, which inhibit the DPP-4 enzyme that normally inactivates the incretin gut hormones GLP-1 and GIP. The patients studied exhibited a safety and tolerability profile similar to placebo. In addition, patients taking Sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia. Patients treated with glipizide had an average weight gain of 1.1 kilogram relative to placebo. Adverse event reports of hypoglycaemia were observed in 4 percent of patients taking Sitagliptin, 17 percent of patients taking glipizide and 2 percent of patients taking placebo.

Results from the studies conducted to date are very promising and ongoing Phase III trials are expected to provide greater insight into the efficacy and tolerability profile of Sitagliptin over a longer period of time.


'"/>




Related medicine news :

1. Undertaking the obesity epidemic
2. Breast Cancer in Men Often Underestimated and Under-treated
3. Drug to Lower Cholesterol Underused
4. Understanding The Predictors Of Prostate Cancer
5. Understanding Restless Legs Syndrome
6. Understanding Lung Cancer Metastasis
7. Understanding The Link Between Hormone Replacement and Respiratory Disease
8. Understanding The Risks Of Hormone Therapy
9. Understanding The Link Between Metabolic Syndrome And Drinking Patterns
10. A Better Understanding Of The Brain Network
11. Understanding The Predictor’s Of Alzheimer’s Diseae
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: